Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
Sean Wharton, Salvatore Calanna, Melanie J. Davies, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 1, pp. 94-105
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff, et al.
The Lancet (2023) Vol. 402, Iss. 10402, pp. 613-626
Open Access | Times Cited: 327
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Filip K. Knop, Vanita R. Aroda, Ruben D do Vale, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 705-719
Closed Access | Times Cited: 188
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen, et al.
The Lancet (2023) Vol. 402, Iss. 10403, pp. 720-730
Closed Access | Times Cited: 148
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Juan José Gorgojo Martínez, Pedro Mezquita‐Raya, Juana Carretero Gómez, et al.
Journal of Clinical Medicine (2022) Vol. 12, Iss. 1, pp. 145-145
Open Access | Times Cited: 112
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
Vicky Chuong, Mehdi Farokhnia, Sophia Khom, et al.
JCI Insight (2023) Vol. 8, Iss. 12
Open Access | Times Cited: 84
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Yamin Shu, Xu‐Cheng He, Pan Wu, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 77
Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort
Wafa Ali Aldhaleei, Tadesse Melaku Abegaz, Akshaya Srikanth Bhagavathula
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 199-199
Open Access | Times Cited: 22
Nutritional considerations with antiobesity medications
Jaime P. Almandoz, Thomas A. Wadden, Colleen Tewksbury, et al.
Obesity (2024) Vol. 32, Iss. 9, pp. 1613-1631
Open Access | Times Cited: 21
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 18
Sex-Specific Factors Influencing Obesity in Women: Bridging the Gap Between Science and Clinical Practice
Hazem Ayesh, Samar A. Nasser, Keith C. Ferdinand, et al.
Circulation Research (2025) Vol. 136, Iss. 6, pp. 594-605
Closed Access | Times Cited: 3
Semaglutide for the treatment of obesity
Ariana M. Chao, Jena Shaw Tronieri, Anastassia Amaro, et al.
Trends in Cardiovascular Medicine (2021) Vol. 33, Iss. 3, pp. 159-166
Open Access | Times Cited: 85
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
Xueqin Gao, Xiaoli Hua, Xu Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 53
New therapies for obesity
Dimitris Papamargaritis, Carel W. le Roux, Jens J. Holst, et al.
Cardiovascular Research (2022) Vol. 119, Iss. 18, pp. 2825-2842
Open Access | Times Cited: 42
Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension
Nik Krajnc, Bianca Itariu, Stefan Macher, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 29
Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta‐analysis including the 2‐year STEP 5 trial
Wenhui Qin, Jun Yang, Chao Deng, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 911-923
Open Access | Times Cited: 27
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns, Elizabeth H. Tressler, Leandro F. Vendruscolo, et al.
Pharmacological Research (2024) Vol. 207, pp. 107312-107312
Open Access | Times Cited: 12
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2024) Vol. 173, pp. 171149-171149
Open Access | Times Cited: 11
Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities
Sahana Bettadapura, Katherine Dowling, Kelli Jablon, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 10
The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: an anti-atherosclerotic action
Κλεοπάτρα Αλεξιάδου, Adam Hartley, Tricia M-M. Tan, et al.
Trends in Cardiovascular Medicine (2024)
Open Access | Times Cited: 10
Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map
Tingting Lu, Bin Liu, Long Ge, et al.
International Journal of Obesity (2025)
Closed Access | Times Cited: 1
Alternative dosing regimens of GLP‐1 receptor agonists may reduce costs and maintain weight loss efficacy
Anıl Cengiz, Calvin Wu, Sean D. Lawley
Diabetes Obesity and Metabolism (2025)
Open Access | Times Cited: 1
Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations
Ariana M. Chao, Jena Shaw Tronieri, Anastassia Amaro, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 4449-4461
Open Access | Times Cited: 38
Mechanisms of lipotoxicity‐induced dysfunction and death of human pancreatic beta cells under obesity and type 2 diabetes conditions
Thomas Plötz, Sigurd Lenzen
Obesity Reviews (2024) Vol. 25, Iss. 5
Open Access | Times Cited: 8
What is the evidence regarding the safety of new obesity pharmacotherapies
Josép Vidal, Lílliam Flores, Amanda Jiménez, et al.
International Journal of Obesity (2024)
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top